Drugs / Mulberry Twig Alkaloids
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06490263 | May → Oct 2024 | morbid obesity | Beijing Wehand-Bio Pharmaceutical Co., Ltd | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-04-14 | Beijing Wehand-Bio Pharmaceutical Co., Ltd | Results 桑枝总生物碱临床研究在糖尿病国际顶级期刊《Diabetes Care》发表 wehandbio.com ↗
研究结果显示桑枝总生物碱可降低糖化血红蛋白0.93%，糖化血红蛋白达标为47.7%，与化学对照药相当，但胃肠不良反应减少近一半。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-04-14 | Beijing Wehand-Bio Pharmaceutical Co., Ltd | 桑枝总生物碱临床研究在糖尿病国际顶级期刊《Diabetes Care》发表 wehandbio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mulberry Twig Alkaloids | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06490263 ↗ |
| Route | Oral | “Administered by swallowing after meals” NCT06490263 ↗ |